Facilitate the transition of projects from the laboratory to the clinic. Translational researchers seek to apply basic knowledge of cancer and bring the benefits of the new basic-level understandings to patients more quickly and efficiently. These grants are $600,000, three-year commitments
Vaccines that prime a patient’s own immune system to attack cancer are an attractive strategy, with the potential to promote durable regression of cancer that is not subject to rapid treatment resistance. However, to date cancer vaccines have generally failed in two important ways to optimally target cancer: First, cancer vaccines have typically targeted proteins that are over-expressed by tumor cells but not necessarily unique to tumor cells- this can lead to poor potency and the danger of autoimmune reactions. Second, vaccines based on peptides, proteins, or whole cell lysates have generally shown poor immunogenicity in patients, due in part to poor uptake of such vaccines by the immune system. We propose the translational development of a novel vaccine platform that addresses these two key limitations and could further be combined with promising immunomodulators such as checkpoint blockade therapies in patients to promote potent but safe anti-tumor immunity. In collaboration with the Broad Institute and the Dana Farber Cancer Institute (DFCI), we are pursuing cancer vaccines that are generated by sequencing the genome of individual patient tumors, and then forming vaccines that are chemically designed to traffic to lymph nodes following injection. We will carry out preclinical safety and manufacturing studies to enable clinical trials of this concept, which has shown great promise in small animal models of cancer therapy. We hypothesize that combining these two promising cancer vaccine technologies will lead to a highly potent, patient-targeted cancer vaccine strategy that could be broadly applied to diverse tumors.
Protein kinases are a family of 518 human proteins which receive and transmit information within the cell, often from one kinase to another. The information flow within the network governs all aspects of cell biology, including cell growth, movement and survival. Not surprisingly, cancer very often re-wires kinase activity and connectivity to support its uncontrolled growth and metastasis. Indeed, protein kinases are the most commonly mutated protein family in human cancer. Protein kinases are also exceptionally ‘druggable’ and constitute the most tractable class of new therapeutic targets. Two significant challenges exist. First, we know a great deal about very few protein kinases. There is no doubt that targeting understudied kinases in cancer will benefit patients, but what kinases and for which patients? Second, several kinase inhibitors have proven immensely effective in certain cancers, however not all patients respond and for those that do respond, resistance inevitably emerges. We now know that cancer reprograms the kinase network to bypass chemotherapy. To tackle these challenges, we have developed a new technology that allows us to identify and quantify the activity of nearly all kinases in a single experiment. This allows us to comparatively study kinase activity in normal cells and in cancer cells, in chemotherapy-sensitive and resistant cancers, and in tumors before and after relapse. We hypothesize that the responsiveness of cancer to targeted therapy is determined by the baseline activity of specific kinases and the nature by which these activities adapt to therapeutic challenge. We will test this hypothesis in tumors of the lungs and head and neck. Together, our experiments may lead to the identification of specific kinase activities which: 1) predict cancer disease progression, 2) predict response to therapy, and 3) suggest new and rationally designed therapeutic strategies for patients with naïve and relapsed cancer.
In the era of Precision Medicine, the treatment of Acute Myeloid Leukemia (AML) remains a significant challenge with fewer than 50% of patients having long term disease-free survival. Yet, the explosion of genomic information has allowed us to refine our knowledge of the genetic changes that result in the development of the many subsets of AML and has provided us insights into new and potentially groundbreaking clinical advances. One of the most common subsets of AML that affects both children and adults is characterized by mutations in a gene important for normal blood cell growth and development known as FLT3. The FLT3 gene is mutated or abnormally expressed in up to 25% of cases of AML and this abnormal expression results in an aberrantly active FLT3 kinase that results in a rapidly proliferating AML with a poor treatment outcome in all patient age groups. Therefore, specific therapies for FLT3 mutant leukemias are needed urgently. Attempts to target the mutant FLT3 with targeted FLT3 kinase inhibitors is an area of active research but a major breakthrough has not yet been made; in part, this is due to the rapid emergence of resistance to the targeted FLT3 kinase inhibitors that have thus far been tested. In this application, we propose the development of a new agent to treat leukemias with mutation or over-expression of FLT3. Recently, our group identified that a protein kinase, known as TOPK, which is abnormally expressed in many cancers (but not in normal tissues) is also expressed in high levels in AML, particularly in AML cells with mutations of FLT3. The laboratory of Dr. Yusuke Nakamura, one of the principal investigators of this grant identified a specific inhibitor of TOPK which is now being developed in partnership with a Japanese company, OncoTherapy Science. They are now completing toxicity and large animal model feasibility testing. Importantly, Dr. Nakamura’s laboratory has developed other successful new protein kinase inhibitors in collaboration with OncoTherapy Science, including a MELK protein kinase inhibitor that is currently being tested for the first time in patients with a variety of solid tumor malignancies here at the University of Chicago. We have tested the TOPK inhibitor OTS514 in many AML cell lines and in cells from patients with AML. Interestingly, this TOPK inhibitor has tremendous activity against AML cells, particularly in those with FLT3 mutations, resulting in their cell death using clinically achievable concentrations of the drug. Importantly, the TOPK inhibitor, OTS514, does not impair the survival of normal early blood cells. The goal of our grant is to understand how it is that the TOPK inhibitor kills FLT3 driven leukemias, to perform pre-clinical testing of OTS514 in mouse models of FLT3 leukemias and, using these insights, to design and perform a first in human trial of this TOPK inhibitor in patients with AML, focusing on those with mutations in FLT3. Our proposal is a comprehensive bench to bedside approach! The ability to shut down FLT3 expression with TOPK inhibition also provides the potential for circumventing the resistance that occurs with targeted FLT3 kinase inhibitors. Thus, we are optimistic that understanding of the mechanism by which TOPK impairs FLT3 driven leukemia cell growth and survival and the performance of a phase I “first in human” trial will provide us with the insights needed for future successful development of this TOPK inhibitor, with the ultimate goal of using a Precision Medicine approach to improving the survival of patients with FLT3 mutated AML.
We are proposing in this V Foundation Translational Grant application to continue to transition C188-9, a small-molecule inhibitor of the cancer-causing protein, Stat3, into an oral drug for use in treating patients with breast cancer and cancer cachexia. The target cancer is a subtype of breast cancer for which there currently are no available targeted therapies in the clinic i.e. breast cancers that do not express the estrogen receptor (ER-), the progesterone receptor (PR-) or the human epidermal growth factor receptor (HER) 2 receptor (HER2-). This subtype of breast cancer, often referred to as triple-negative breast cancer (TNBC), accounts for 20% of breast cancer, is characterized by an aggressive phenotype, is preferentially found in younger women and in African-American women, and has been associated with poor prognosis. Recent studies by us and others has demonstrated that Stat3 is activated in 70% of TNBC tested and that Stat3 activity makes a critical contribution to the growth of these tumors. Thus, Stat3 may be a key target in this subtype of breast cancer. We have developed the capability of testing C188-9 for its ability to inhibit the growth in mice of TNBC tumors that have been transplanted directly from patients. This capability allows us to determine accurately whether or not a patient with TNBC will respond to C188-9. Thus far, we have tested C188-9 in two TNBC patient-derived xenograft (TN-PDX) models in which activation of Stat3 was demonstrated. One TN-PDX model was resistant to standard chemotherapy (docetaxel), while the second TN-PDX model was sensitive to docetaxel. We observed a striking benefit in both models when C188-9 treatment was added to docetaxel. The docetaxel-resistant TN-PDX was converted to docetaxelsensitive by the addition of C188-9, while the docetaxel responsive TN-PDX demonstrated an improved tumor response by shrinking 4-fold further with the addition of C188-9. We have determined that C188-9 given by mouth at high doses is quite safe in mice, rats and dogs. C188-9 also reached high levels in the bloodstream and tumors borne by these animals with 2-fold higher levels being achieved in the tumors than in the bloodstream. As outlined in this proposal (Aim 1), we plan to perform an animal clinical trial using 23 TN-PDX models, and thereby learn the breadth of responses to C188-9 we can expect in patients with TNBC. This information will be very useful for designing clinical trials to test the effect of C188-9 in combination with docetaxel in TNBC patients. The animal clinical trial will also allow us to determine if reduction in the level of activated Stat3 in blood cells and in tumors can serve as a marker that we can follow in patients as evidence of successful targeting of Stat3 by C188-9.
Cachexia is the second clinical application for C188-9 that we are exploring in this proposal. Cachexia is the muscle wasting process causing progressive muscle weakness in nearly all patients with cancer. Cancer cachexia is a major cause of morbidity and reduced quality of life in patients with cancer, including breast cancer, and it directly causes up to 25% of all cancer deaths. We recently demonstrated that cachexia in cancer involves a signaling pathway within skeletal muscles that links Stat3 activation with upregulation of myostatin, a hormone that serves as the major negative regulator of muscle mass. Targeting myostatin in mouse models of cancer cachexia not only reversed cachexia but also improved survival despite continued growth of tumor. However, patients with cachexia who have been treated with direct myostatin inhibitors developed unexplained bleeding, which has halted further testing of this approach. We demonstrated that C188-9 treatment of mice with tumors that cause cachexia prevents activation of Stat3 within their skeletal muscles. Consequently, levels of myostatin were not increased and muscle wasting was prevented. Importantly, treatment with C188-9 did not cause any ill effects in mice. In fact, tumor-bearing mice treated with C188-9 gained weight and maintained muscle strength. One of the goals of the clinical trials outlined in Aim 2 of this proposal is to begin to determine if C188-9 treatment of patients with TNBC prevents them from developing muscle loss, weakness, and/or fatigue.
The successful completion of the studies outlined in this proposal will provide additional strong support for the overarching concept that C188-9 can be used safely and effectively as an oral agent to treat patients with breast cancer, particularly TNBC, in combination with standard chemotherapy to improve therapeutic responses, as well as to prevent cancer cachexia.
